The largest Insider Buys this week were for Intercept Pharmaceuticals Inc. (ICPT, Financial), Cloudera Inc. (CLDR, Financial), OPKO Health Inc. (OPK, Financial) and Entercom Communications Corp. (ETM, Financial).
Intercept Pharmaceuticals director bought 7,812 shares
Director Daniel Bradbury bought 7,812 shares of Intercept stock on April 9 at the average price of $64 per share. The stock price has increased by 14.17% since then.
Intercept Pharmaceuticals is a biopharmaceutical company that focuses on the development of novel synthetic bile acid analogs to treat chronic liver diseases. The company focuses on diseases such as primary biliary cirrhosis and primary sclerosing cholangitis. The company has a market capitalization of $2.15 billion, and as of April 13 it traded at $73.07.
On April 13, Intercept Pharmaceuticals announced clinical data from a liver biopsy-based substudy from the POISE Phase 3 trial, suggesting that long-term obeticholic acid treatment in patients with primary biliary cholangitis was associated with reversal or stabilization of fibrosis and cirrhosis. The data was presented at the 53rd Annual Meeting of the European Association for the Study of the Liver in Paris.
Cloudera director bought 25,000 shares
Director Michael A. Stankey bought 25,000 shares of Cloudera stock on April 9 at the average price of $12.99. The price of the stock has increased by 7.08% since then.
Cloudera is an American software development company that provides Apache Hadoop and Apache Spark-based software, support and services to business customers. The company’s hybrid open source Apache Hadoop distribution targets enterprise class deployments of that technology. Cloudera is also a sponsor of the Apache Software Foundation. The company has a market capitalization of $2.05 billion, and as of April 13 traded at $13.91.
On April 9, the company announced a partnership with Simudyne, a leading simulation software company. The two companies will bring the first computational simulation platform built for big data to the financial sector. The partnership aims to provide banks and financial companies with the ability to run detailed simulation models at massive scales.
OPKO Health director bought 10,000 shares
Director Robert Scott Fishel bought 10,000 shares of OPKO stock on April 6 at the average price of $3.16. The stock price has declined 5.38% since then.
OPKO Health is an American pharmaceutical and medical test company. The company is mainly focused on diagnostics and pharmaceuticals, but also develops treatments for secondary hyperparathyroidism. The company recently finished the patient recruitment for a Phase III trial against insufficiency in vitamin D. In 2014, it acquired Laboratorio Arama de Uruguay. The company has a market capitalization of $1.67 billion, and as of April 13 it traded at $2.99.
On March 23, OPKO announced it has enrolled the first patient in a phase 2b dose escalation trial of OPK88003, a once weekly oxyntomodulin therapy to treat type 2 diabetes and obesity. Based on preclinical and phase 2 data, the therapy could more effectively improve glucose control and increase weight loss.
Entercom Communications chairman emeritus bought 375,000 shares
Chairman Emeritus Joseph M. Field bought 375,000 shares of Entercom stock on April 11 at the average price of $9.7. The stock price has fallen 0.52% since then.
Entercom is an American broadcasting and radio network company. It is the second-largest radio company in the United States with 235 radio stations across 48 media markets. Last November, Entercom merged with CBS Radio. The company has a market capitalization of $1.37 billion, and as of April 13 it traded at $9.65.
On April 11, Entercom Communications announced plans to relaunch 97.3 as 97.3 THE FAN as San Diego’s only 24/7 all-sports FM station. The station will serve as the flagship home for the San Diego Padres and will broadcast all regular season games. The new format launched on April 12.
For the complete list of stocks that were bought by their company executives, go to Insider Trades.
Disclosure: I do not own stock in any of the companies mentioned in the article.
